Zetia, Vytorin CV Risk Reduction Claim Fails To Win FDA Panel Backing
This article was originally published in The Pink Sheet Daily
Executive Summary
Panelists cite modest efficacy benefit and concerns about statistical robustness in Merck's IMPROVE-IT trial; despite negative vote, some committee members suggest narrower claim that more closely resembles patient population in the large outcomes study.